<DOC>
	<DOCNO>NCT02931539</DOCNO>
	<brief_summary>The purpose study determine investigational treatment ( Maribavir ) safe effective treating transplant recipient patient cytomegalovirus ( CMV ) infection refractory resistant treatment .</brief_summary>
	<brief_title>Efficacy Safety Maribavir Transplant Recipients With Cytomegalovirus ( CMV ) Infections That Are Refractory Resistant Treatment</brief_title>
	<detailed_description />
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Cidofovir</mesh_term>
	<mesh_term>Foscarnet</mesh_term>
	<criteria>1 . Be able provide write , personally sign , date informed consent participate study complete studyrelated procedure . As applicable , parent/both parent legally authorize representative ( LAR ) must provide signature informed consent must documentation assent subject completing studyrelated procedure . 2 . Be recipient hematopoietic stem cell solid organ transplant . 3 . Have document CMV infection 910 ≥IU/ml blood plasma sample , two consecutive assessment separate least one day , take within 14 day prior randomization second sample obtain within 5 day prior randomization . 4 . Have current CMV infection refractory resistant current treatment . Refractory define failure &gt; 1log10 decrease CMV viral load within minimum 2 week treatment ganciclovir , valganciclovir , foscarnet cidofovir . 5 . Per Investigator 's judgment , eligible treatment least one available antiCMV drug ( ganciclovir , valganciclovir , foscarnet , cidofovir ) . 6 . Weight ≥35 kg . 7 . Have follow result part screen laboratory assessment ( result either central laboratory local laboratory use qualification ) : 1 . Absolute neutrophil count ( ANC ) ≥1000/mm3 [ 1.0 x 109/L ] 2 . Platelet count ≥25,000/mm^3 [ 25 x 10^9/L ] , 3 . Hemoglobin ≥8g/dL . 4 . Estimated glomerular filtration rate ( eGFR ) &gt; 30 mL/min/1.73m^2 assess Modification Diet Renal Disease ( MDRD ) formula subject ≥18 year age Schwartz formula subject &lt; 18 year age . 8 . All female child bear potential must negative pregnancy test screening . Sexually active female child bear potential must agree comply applicable contraceptive requirement protocol . If male , must agree use acceptable method birth control , define protocol , study treatment administration period 90 day afterward treat maribavir , ganciclovir , valganciclovir , cidofovir 180 day afterward treat foscarnet . 9 . Be able swallow tablet , receive crush tablet via nasogastric orogastric tube . 10 . Be willing understanding ability fully comply study procedure restriction define protocol . 11 . Be willing provide necessary sample ( eg , biopsy ) diagnosis tissue invasive CMV disease Baseline determine Investigator . 12 . Life expectancy ≥ 8 week . 1 . Have current CMV infection consider refractory resistant due inadequate adherence prior antiCMV treatment , best knowledge Investigator . 2 . Requires ganciclovir , valganciclovir , foscarnet , cidofovir administration condition CMV study treatment initiated NOTE : A subject continue antiCMV drug ( ) ( ganciclovir , valganciclovir foscarnet ) study must discontinue use first dose study drug . If subject currently receive cidofovir assign another antiCMV agent investigator subject must discontinue use least 14 day prior randomization Visit 2/Day 0 first dose study treatment . 3 . Be receive leflunomide , artesunate study treatment initiate . NOTE : Subjects may receive leflunomide must discontinue use least 14 day prior randomization Visit 2/Day 0 first dose study treatment . Subjects receive artesunate must discontinue use prior first dose study treatment . 4 . Have severe vomiting , diarrhea , severe gastrointestinal illness within 24 hour prior first dose study treatment would preclude administration oral/enteral medication . 5 . Have know hypersensitivity active substance excipient study treatment . 6 . Have tissue invasive CMV disease central nervous system involvement . 7 . Serum aspartate aminotransferase ( AST ) &gt; 5 time upper limit normal ( ULN ) screening , serum alanine aminotransferase ( ALT ) &gt; 5 time ULN screening , total bilirubin ≥3.0 x ULN screening ( except document Gilbert 's syndrome ) , local central lab . Subjects CMV hepatitis exclude despite &gt; 5 time ULN screening . 8 . Have positive result human immunodeficiency virus ( HIV ) . Subjects must confirm negative result within 3 month study entry willing test Screening 9 . Require mechanical ventilation vasopressor hemodynamic support time enrollment . 10 . Be female pregnant breast feed 11 . Have previously receive maribavir . 12 . Have receive investigational agent know antiCMV activity within 30 day initiation study treatment investigational antiCMV vaccine time . 13 . Have active malignancy exception nonmelanoma skin cancer . Subjects HSCT experience relapse progression malignancy per investigator 's opinion enrol . 14 . Undergoing treatment acute chronic hepatitis C. 15 . Have clinically significant medical surgical condition , Investigator 's opinion , could interfere interpretation study result , contraindicate administration assign study treatment , compromise safety wellbeing subject .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>